US 12,337,029 B2
Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof
Tyler Brown, Cambridge, MA (US); and Kelly Ibsen, Boston, MA (US)
Assigned to I2O THERAPEUTICS, INC., Cambridge, MA (US)
Filed by i2O Therapeutics, Inc., Cambridge, MA (US)
Filed on Feb. 16, 2024, as Appl. No. 18/444,485.
Application 18/444,485 is a continuation of application No. PCT/US2022/049585, filed on Nov. 10, 2022.
Claims priority of provisional application 63/277,878, filed on Nov. 10, 2021.
Claims priority of provisional application 63/295,197, filed on Dec. 30, 2021.
Claims priority of provisional application 63/334,410, filed on Apr. 25, 2022.
Claims priority of provisional application 63/380,125, filed on Oct. 19, 2022.
Prior Publication US 2024/0325323 A1, Oct. 3, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/26 (2006.01); A61K 9/08 (2006.01); A61K 31/14 (2006.01); A61K 38/22 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); C07K 14/575 (2006.01); C07K 14/605 (2006.01); C07K 16/24 (2006.01); A61K 38/00 (2006.01)
CPC A61K 38/26 (2013.01) [A61K 9/08 (2013.01); A61K 31/14 (2013.01); A61K 38/22 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01); A61K 47/186 (2013.01); A61K 47/542 (2017.08); A61K 47/6845 (2017.08); C07K 14/575 (2013.01); C07K 14/605 (2013.01); C07K 16/241 (2013.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01)] 27 Claims
 
1. A compound having the structure of Formula I:

OG Complex Work Unit Chemistry
wherein:
R1, R2, and R3 are independently C1-C5alkyl, wherein at least one of R1, R2, and R3 is C2-C5 alkyl;
R4 is C2-C5 alkyl, wherein the C2-C5 alkyl is unsubstituted or substituted with 1 or more hydroxyl; and

OG Complex Work Unit Chemistry
 is a therapeutic agent having the following configuration:
[diacid]-[linker]-[an amylin analog];
wherein the amylin analog has the amino acid sequence of
 
 (SEQ ID NO: 20)
 
 KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-amide,
 with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof; and
wherein the compound has a

OG Complex Work Unit Chemistry
molar ratio of from about 1:1 to about 1:3.